Bibliography
- American Academy of Sleep Medicine. Sleep starts (hypnic jerks). In: Sateia M, editor, The International Classification of Sleep Disorders: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine, 2005. p. 208-210
- Fahn S CM, Van Woert MH. Definition and classification of myoclonus. In: Fahn S, editor, Advances in neurology. New York: Raven Press, 1986. p. 1-5
- Shibasaki H, Hallett M. Electrophysiological studies of myoclonus. Muscle Nerve 2005;31:157-74
- Koskiniemi M, Donner M, Majuri H, et al. Progressive myoclonus epilepsy. A clinical and histopathological study. Acta Neurol Scand 1974;50:307-32
- Genton PD, Charlot C. Treatment of epilepsies with myoclonia. In: DF Shorvon S, Fish D, Thomas D, editors, The Treatment of Epilepsy. Oxford: Blackwell, 1996. p. 247-57
- Iivanainen M, Himberg JJ. Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol 1982;39:236-8
- Henry TR, Leppik IE, Gumnit RJ, et al. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988;38:928-31
- Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998;29:109-14
- Vossler DG, Conry JA, Murphy JV. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord 2008;10:31-4
- Genton P, Guerrini R, Remy C. Piracetam in the treatment of cortical myoclonus. Pharmacopsychiatry 1999;32(Suppl 1):49-53
- Kinrions P, Ibrahim N, Murphy K, et al. Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy. Neurology 2003;60:1394-5
- Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004;45:678-81
- Hurd RW, Wilder BJ, Helveston WR, et al. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology 1996;47:1264-8
- Edwards MJ, Hargreaves IP, Heales SJ, et al. N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects. Neurology 2002;59:1447-9
- Genton P, Gelisse P, Crespel A. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia 2006;47:2083-5
- Uldall P, Buchholt JM. Clinical experiences with topiramate in children with intractable epilepsy. Eur J Paediatr Neurol 1999;3:105-11
- Eldridge R, Iivanainen M, Stern R, et al. ‘Baltic‘ myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983;2:838-42
- Andrade DM, Turnbull J, Minassian BA. Lafora disease, seizures and sugars. Acta Myol 2007;26:83-6
- Franceschetti S, Gambardella A, Canafoglia L, et al. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia 2006;47:640-3
- Singh S, et al. Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population. J Hum Genet 2005;50:347-52
- Heycop TV. Lafora disease, a form of progressive myoclonus epilesy. In: BG Vinken PJ, editor, The Epilepsies. Handbook of Clinical Neurology. Vol. 15. Amsterdam: North-Holland, 1974. p. 382-422
- Minassian BA. Lafora's disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol 2001;25:21-9
- Yoshimura I, Kaneko S, Yoshimura N, et al. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res 2001;46:283-7
- Aykutlu E, Baykan B, Gurses C, et al. Add-on therapy with topiramate in progressive myoclonic epilepsy. Epilepsy Behav 2005;6:260-3
- Cardinali S, Canafoglia L, Bertoli S, et al. A pilot study of a ketogenic diet in patients with Lafora body disease. Epilepsy Res 2006;69:129-34
- Aberg LE, Backman M, Kirveskari E, et al. Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis. Epilepsia 2000;41:1296-302
- Aberg L, Heiskala H, Vanhanen SL, et al. Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL). Neuropediatrics 1997;28:77-9
- Dravet CB, Bureau M, Guerrini R, et al. Severe myoclonic epilepsy in infants. In: BM Roger J, Dravet C, Dreifuss FE, Perret A, Wolf P, editors, Epileptic Syndromes in Infancy, Childhood and Adolescence. London: Libbey, 1992. p. 75-88
- Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998;29:147-54
- Guerrini R, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12
- Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000;356:1638-42
- Thanh TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome). Arch Pediatr 2002;9:1120-7
- Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007;69:250-4
- Labate A, Colosimo E, Gambardella A, et al. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 2006;15:214-18
- Tanabe T, Awaya Y, Matsuishi T, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome) – a nationwide questionnaire survey in Japan. Brain Dev 2008;30:629-35
- Coppola G, Capovilla G, Montagnini A, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res 2002;49:45-8
- Nieto-Barrera M, Candau R, Nieto-Jimenez M, et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000;9:590-4
- Saito Y, Oguni H, Awaya Y, et al. Phenytoin-induced choreoathetosis in patients with severe myoclonic epilepsy in infancy. Neuropediatrics 2001;32:231-5
- Jeavons PM, Clark JE. Sodium valproate in treatment of epilepsy. Br Med J 1974;2:584-6
- Clancy RR. Valproate: an update – the challenge of modern pediatric seizure management. Curr Probl Pediatr 1990;20:161-233
- Wheless JW, Constantinou JE. Lennox-Gastaut syndrome. Pediatr Neurol 1997;17:203-11
- Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome. N Engl J Med 1993;328:29-33
- Siegel H, Kelley K, Stertz B, et al. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsy Res 1999;34:91-7
- Yeung S, Ferrie CD, Murdoch-Eaton DG, et al. Topiramate for drug-resistant epilepsies. Eur J Paediatr Neurol 2000;4:31-3
- Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998;39:495-501
- Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003;3:CD003277
- Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997;337:1807-12
- Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52:1882-7
- French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-73
- Guerrini R, et al. Myoclonic status epilepticus following high-dosage lamotrigine therapy. Brain Dev 1999;21:420-4
- Weber S, Beran RG. A pilot study of compassionate use of Levetiracetam in patients with generalised epilepsy. J Clin Neurosci 2004;11:728-31
- De Los Reyes EC, Sharp GB, Williams JP, et al. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol 2004;30:254-6
- Chamberlain MC. Nitrazepam for refractory infantile spasms and the Lennox-Gastaut syndrome. J Child Neurol 1996;11:31-4
- You SJ, Kang HC, Kim HD, et al. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev 2008;30:287-90
- Hakimian S, Cheng-Hakimian A, Anderson GD, et al. Rufinamide: a new anti-epileptic medication. Expert Opin Pharmacother 2007;8:1931-40
- Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70:1950-8
- Dulac O, Chiron C, Luna D, et al. Vigabatrin in childhood epilepsy. J Child Neurol 1991;(Suppl 2):30-7
- Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996;46:852-3
- Dulac O, N'Guyen T. The Lennox-Gastaut syndrome. Epilepsia 1993;34(Suppl 7):7-17
- Sorenson JM, Wheless JW, Baumgartner JE, et al. Corpus callosotomy for medically intractable seizures. Pediatr Neurosurg 1997;27:260-7
- Guerrini R, De Lorey TM, Bonanni P, et al. Cortical myoclonus in Angelman syndrome. Ann Neurol 1996;40:39-48
- Stecker MM, Myers SM. Reserpine responsive myoclonus and hyperpyrexia in a patient with Angelman syndrome. Clin Neurol Neurosurg 2003;105:183-7
- Espay AJ, Andrade DM, Wennberg RA, et al. Atypical absences and recurrent absence status in an adult with Angelman syndrome due to the UBE3A mutation. Epileptic Disord 2005;7:227-30
- Laan LA, den Boer AT, Hennekam RC, et al. Angelman syndrome in adulthood. Am J Med Genet 1996;66:356-60
- Sugiura C, Ogura K, Ueno M, et al. High-dose ethosuximide for epilepsy in Angelman syndrome: implication of GABA(A) receptor subunit. Neurology 2001;57:1518-19
- Dion MH, Novotny EJ, Jr., Carmant L, et al. Lamotrigine therapy of epilepsy with Angelman's syndrome. Epilepsia 2007;48:593-6
- Franz DN, Glauser TA, Tudor C, et al. Topiramate therapy of epilepsy associated with Angelman's syndrome. Neurology 2000;54:1185-8
- Oguni H, Tanaka T, Hayashi K, et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002;33:122-32
- Doose H. Myoclonic-astatic epilepsy. Epilepsy Res Suppl 1992;6:163-8
- Neubauer BA, Hahn A, Doose H, et al. Myoclonic-astatic epilepsy of early childhood – definition, course, nosography, and genetics. Adv Neurol 2005;95:147-55
- Kilaru S, Bergqvist AG. Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia. Epilepsia 2007;48:1703-7
- Auvin S, Pandit F, De Bellecize J, et al. Benign myoclonic epilepsy in infants: electroclinical features and long-term follow-up of 34 patients. Epilepsia 2006;47:387-93
- Mangano S, Fontana A, Cusumano L. Benign myoclonic epilepsy in infancy: neuropsychological and behavioural outcome. Brain Dev 2005;27:218-23
- Cuvellier JC, Lamblin MD, Cuisset JM, et al. Benign reflex myoclonic epilepsy in infants. Arch Pediatr 1997;4:755-8
- Todt H, Muller D. The therapy of benign myoclonic epilepsy in infants. Epilepsy Res Suppl 1992;6:137-9
- Capovilla G, Beccaria F, Gambardella A, et al. Photosensitive benign myoclonic epilepsy in infancy. Epilepsia 2007;48:96-100
- Bech P, Pedersen K, Simonsen N, et al. A multidimensional study of personality traits ad modum Sjobring. Acta Neurol Scand 1976;54:348-58
- Penry JK, Dean JC, Riela AR. Juvenile myoclonic epilepsy: long-term response to therapy. Epilepsia 1989;30(Suppl 4):19-23; discussion 24-7
- Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(Suppl 1):1-56; quiz 59-60
- Morris GL, Hammer AE, Kustra RP, et al. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav 2004;5:509-12
- Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5149-51
- Gericke CA, Picard F, de Saint-Martin A, et al. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study. Epileptic Disord 1999;1:159-65
- Levisohn PM, Holland KD. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy Behav 2007;10:547-52
- Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008;70:607-16
- Di Bonaventura C, Fattouch J, Mari F, et al. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord 2005;7:231-5
- Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 2003;12:617-20
- Betts T, Yarrow H, Greenhill L, et al. Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study. Seizure 2003;12:136-40
- Verrotti A, Cerminara C, Coppola G, et al. Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Dev Med Child Neurol 2008;50:29-32
- Welty TE, Martin JE, Faught E, et al. Comparison of outcomes in patients with juvenile myoclonic epilepsy treated with lamotrigine, topiramate, zonisamide, or levetiracetam. Epilepsia 2002;43(Suppl 7): Abstract F.03
- Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004;6:267-70
- O'Rourke D, Flynn C, White M, et al. Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: retrospective evidence from an Irish compassionate-use case series. Iran Med J 2007;100:431-3
- Verrotti A, Cerminara C, Domizio S, et al. Levetiracetam in absence epilepsy. Dev Med Child Neurol 2008;50:850-3
- Rocamora R, Wagner K, Schulze-Bonhage A. Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy. Seizure 2006;15:428-33
- Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol 2000;15(Suppl 1):7-13
- Manonmani V, Wallace SJ. Epilepsy with myoclonic absences. Arch Dis Child 1994;70:288-90
- Jeavons PM, Clark JE, Maheshwari MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate (‘epilim’). Dev Med Child Neurol 1977;19:9-25
- Genton PD, Dravet C. Treatment of epilepsies with myoclonia. In: SD Shorvon F, Fish D, Thomas D, editors, The Treatment of Epilepsy. Oxford: Blackwell, 1996. p. 247-57
- Tassinari CAM, Rubboli RG, Passarelli D, et al. Eyelid myoclonia with absences. In: Duncan JP, CP, ed. Typical absences and related epileptic syndromes. London: Churchill Communications Europe; 1995. p. 187-93
- Appleton RE, Panayiotopoulos CP, Acomb BA, et al. Eyelid myoclonia with typical absences: an epilepsy syndrome. J Neurol Neurosurg Psychiatry 1993;56:1312-16
- Striano P, et al. A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). Epilepsia 2008;49:425-30
- Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17
- Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000;22:75-80
- Snead OC 3rd, Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985;313:916-21
- Viani F, Romeo A, Viri M, et al. Seizure and EEG patterns in Angelman's syndrome. J Child Neurol 1995;10:467-71
- Nanba Y, Maegaki Y. Epileptic negative myoclonus induced by carbamazepine in a child with BECTS. Benign childhood epilepsy with centrotemporal spikes. Pediatr Neurol 1999;21:664-7
- Genton P, Gelisse P, Thomas P, et al. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9
- Marciani MG, Maschio M, Spanedda F, et al. Development of myoclonus in patients with partial epilepsy during treatment with vigabatrin: an electroencephalographic study. Acta Neurol Scand 1995;91:1-5
- Kuenzle C, Steinlin M, Wohlrab G, et al. Adverse effects of vigabatrin in Angelman syndrome. Epilepsia 1998;39:1213-15
- Jimenez-Jimenez FJ, Puertas I, de Toledo-Heras M. Drug-induced myoclonus: frequency, mechanisms and management. CNS Drugs 2004;18:93-104
- Ardesch JJ, Buschman HP, Wagener-Schimmel LJ, et al. Vagus nerve stimulation for medically refractory epilepsy: a long-term follow-up study. Seizure 2007;16:579-85
- Asadi-Pooya AA, Sharan A, Nei M, et al. Corpus callosotomy. Epilepsy Behav 2008;13:271-8
- Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 2002;1:477-82
- Buoni S, Mariottini A, Pieri S, et al. Vagus nerve stimulation for drug-resistant epilepsy in children and young adults. Brain Dev 2004;26:158-63
- Chavel SM, Westerveld M, Spencer S. Long-term outcome of vagus nerve stimulation for refractory partial epilepsy. Epilepsy Behav 2003;4:302-9
- Cukiert A, Burattini JA, Mariani PP, et al. Extended, one-stage callosal section for treatment of refractory secondarily generalized epilepsy in patients with Lennox-Gastaut and Lennox-like syndromes. Epilepsia 2006;47:371-4
- DeGiorgio CM, Schachter SC, Handforth A, et al. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 2000;41:1195-200
- Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia 2001;42:1148-52
- Helmers SL, Wheless JW, Frost M, et al. Vagus nerve stimulation therapy in pediatric patients with refractory epilepsy: retrospective study. J Child Neurol 2001;16:843-8
- Holmes MD, Silbergeld DL, Drouhard D, et al. Effect of vagus nerve stimulation on adults with pharmacoresistant generalized epilepsy syndromes. Seizure 2004;13:340-5
- Jenssen S, Sperling MR, Tracy JI, et al. Corpus callosotomy in refractory idiopathic generalized epilepsy. Seizure 2006;15:621-9
- Mapstone TB. Vagus nerve stimulation: current concepts. Neurosurg Focus 2008;25:E9
- Milby AH, Halpern CH, Baltuch GH. Vagus nerve stimulation for epilepsy and depression. Neurotherapeutics 2008;5:75-85
- Nei M, O'Connor M, Liporace J, et al. Refractory generalized seizures: response to corpus callosotomy and vagal nerve stimulation. Epilepsia 2006;47:115-22
- Sunaga S, Shimizu H, Sugano H. Long-term follow-up of seizure outcomes after corpus callosotomy. Seizure 2008;18:124-8
- Wheless JW, Sankar R. Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia 2003;44 (Suppl 11):27-37
- You SJ, Kang HC, Ko TS, et al. Comparison of corpus callosotomy and vagus nerve stimulation in children with Lennox-Gastaut syndrome. Brain Dev 2008;30:195-9
- Amar AP, DeGiorgio CM, Tarver WB, et al. Long-term multicenter experience with vagus nerve stimulation for intractable partial seizures: results of the XE5 trial. Stereotact Funct Neurosurg 1999;73:104-8
- Smith B, Shatz R, Elisevich K, et al. Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia 2000;41:1046-8
- Chabardes S, Kahane P, Minotti L, et al. Deep brain stimulation in epilepsy with particular reference to the subthalamic nucleus. Epileptic Disord 2002;4 (Suppl 3):83-93
- Vesper J, Steinhoff B, Rona S, et al. Chronic high-frequency deep brain stimulation of the STN/SNr for progressive myoclonic epilepsy. Epilepsia 2007;48:1984-9
- Velasco F, Velasco M, Velasco AL, et al. Effect of chronic electrical stimulation of the centromedian thalamic nuclei on various intractable seizure patterns: I. Clinical seizures and paroxysmal EEG activity. Epilepsia 1993;34:1052-64
- Cif L, Valente EM, Hemm S, et al. Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord 2004;19:724-7
- Foncke EM, Bour LJ, Speelman JD, et al Local field potentials and oscillatory activity of the internal globus pallidus in myoclonus-dystonia. Mov Disord 2007;22:369-76
- Liu X, Griffin IC, Parkin SG, et al. Involvement of the medial pallidum in focal myoclonic dystonia: a clinical and neurophysiological case study. Mov Disord 2002;17:346-53
- Magarinos-Ascone CM, Regidor I, Martinez-Castrillo JC, et al. Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatry 2005;76:989-91
- Kossoff EH, Rowley H, Sinha SR, et al. A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia 2008;49:316-19
- Mady MA, Kossoff EH, McGregor AL, et al. The ketogenic diet: adolescents can do it, too. Epilepsia 2003;44:847-51
- Henderson CB, Filloux FM, Alder SC, et al. Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis. J Child Neurol 2006;21:193-8